Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Melanoma Combos Get Mixed Reception From German HTA Body

Executive Summary

Germany’s IQWiG says Mekinist plus Tafinlar offers a “considerable” added benefit in melanoma after surgery, but Braftovi plus Mektovi has not shown an additional benefit over comparator therapy in unresectable or metastatic melanoma.

You may also be interested in...



UK NICE OKs Melanoma Combo Treatment From Array/Pierre Fabre

Array BioPharma/Pierre Fabre’s combination treatment for metastatic melanoma has received NICE's go-ahead for funding under the national health service in England and Wales.

Coronavirus Notebook: EMA Data Hack Aimed At 'Undermining Trust' In Vaccines, Russia Plans EU Sputnik V Filing Next Month

France has reported on side-effect reports concerning the Pfizer/BioNTech vaccine, and the World Health Organization has warned that plans to provide global equitable access to coronavirus vaccines are at risk.

UK Spending £2.9bn On Seven COVID-19 Vaccines

The UK government says it is on track to vaccinate the 15 million most vulnerable people by mid-February, and that a “major study” is under way to assess the potential impact of the new UK variant on vaccine efficacy.

Topics

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel